Clinical Trial

Expertise Asthma COPD Program with Digital Support

Study acronym: EXACT@home
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated March 25, 2025 (before its estimated April 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The aim EXACT@Home is to create an evidence-based health program using e.g. questionnaires, a digital health platform and multiple digital devices to further improve the assessment of patients diagnosed with severe asthma. By better charting treatable traits (e.g. poor adherence, physical inactivity, dysfunctional breathing), we expect to improve the indication for the use of biologics. One the devices that will be used is also a medicinal product: a digital inhaler, which monitors adherence and inhaler technique through its connected application and aims to improve adherence and inhaler technique with reminders and notifications. Next to this an activity tracker, hand-held spirometer and FeNO measuring device will be used. The information of the devices will be collected in a Personal Digital Healthcare Environment (PDHE). Patients diagnosed with severe asthma according to the regional asthma Multi-Disciplinary Team Meeting (MDTM) eligible for a treatment with biologics will be included. Half of the patients will immediately receive a biologic. The other half will first undergo the systematic assessment including home monitoring (=EXACT@home) and afterwards a treatment will be chosen based on this evaluation: optimization of treatable traits when present and/or biologics. The chosen treatment of both, the intervention and control group, will be evaluated during 11-12 months.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-04-14.
Trial Details
NCT Number NCT05831566
Lead Sponsor Franciscus Gasthuis
Collaborators: Teva Pharmaceuticals USA
Conditions Asthma
Enrollment 138 participants
Start Date 2023-01-31
Primary Completion 2025-04-30 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-25